In the last of four blog posts on the challenges of advancing healthcare quality, members of AHRQ’s National Advisory Council highlight that little is known about the current quality of hospice care and how it varies across hospice programs. The authors assert that, as the population ages and older Americans…
New more aggressive targets for blood pressure and lipids are among the changes to the annual American Diabetes Association (ADA) Standards of Care in Diabetes — 2023.
Recommendations made by the USPSTF are independent of the U.S. government. They should not be construed as an official position of the Agency for Healthcare Research and Quality or the U.S. Department of Health and Human Services.
The American College of Cardiology (ACC) and American Heart Association (AHA) have released new guidelines for the diagnosis and management of patients presenting with aortic disease. The in-depth document, published in the Journal of the American College of Cardiology, covers a variety of topics, including thoracic aortic disease, peripheral artery…
For the 20th year, AHRQ is reporting on healthcare quality and disparities. The annual National Healthcare Quality and Disparities Report is mandated by Congress to provide a comprehensive overview of the quality of healthcare received by the general U.S. population and disparities in care experienced by different racial and socioeconomic…
The American College of Cardiology has published a new guidance document focused on the treatment of patients who present with hyperlipidemia and multiple chronic conditions such as hypertension, diabetes and atrial fibrillation:
On September 16th, the Agency for Healthcare Research and Quality (AHRQ) published a Request for Information (RFI) in the Federal Register seeking public comment about comprehensive, longitudinal, person-centered care planning for people at risk for or living with Multiple Chronic Conditions (MCC). We encourage you or others in your organization to review…
Questions about how to prescribe statins for primary prevention abound more than three decades after the drugs swept into clinical practice to become a first-line medical approach to cutting cardiovascular (CV) risk.